Screening LSCs For AML Drug Resistance, Sensitivity
Researchers used high throughput drug screening on leukemic stem cells to determine drug resistance and sensitivity in acute myeloid leukemia patients.
How Useful Are Immune Checkpoint Markers in Squamous Cell Carcinoma?
A recent study examined the literature on whether immune checkpoint molecules improve overall survival in oral squamous cell carcinoma.
Is the FDA’s Biosimilar Action Plan Adequate?
Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.
Disruptive Discovery in Acute Myeloid Leukemia Recurrence
Researchers discovered clinical and experimental evidence that calls into question the widely held notion that LSCs preferentially outlive chemotherapy.
Do Bigger Brains Contribute to More Cancer?
New research published in Neuro-Oncology examines the controversial link between intracranial volume and high-grade glioma.
First Results of Beat AML Master Trial Published
The ground-breaking study, led by the Leukemia & Lymphoma Society, is evaluating several novel targeted therapies for acute myeloid leukemia.
Oncologists Divided Over Prophylactic Cranial Irradiation for NSCLC
Experts discuss the implications of research that found PCI reduces brain metastases in stage III NSCLC, but does not improve overall survival.
Local Consolidative Therapy vs Observation in Limited Metastatic NSCLC
Researchers reported on differences in overall survival for LCT vs maintenance therapy/observation in oligometastatic NSCLC.
New ASCO/SITC Guidance Addresses Shortcomings of Immuno-Oncology Trial Reporting
The recommendations on Trial Reporting in Immuno-Oncology aim to enchance understanding of efficacy and toxicity outcomes in immuno-oncology trials.
Study Sheds Light on Risk of Liver Injury in Combined Immunotherapy
The frequency of hepatotoxic immune-related adverse events varied in patients receiving one vs multiple chemotherapy agents.
Treating Advanced Indolent Follicular Lymphoma Without Chemotherapy
New research evaluated whether symptomatic indolent follicular lymphoma requires new long-term therapy after first-line rituximab without chemotherapy.
The Reality of Cancer Biosimilars: Challenges and New Hope
Various challenges still surround the use of cancer biologics, but expert guidance and expiring patents may help expand their use and benefits.
Study: Best Treatments for Basal Cell Carcinoma
Age, Lymph Node Positivity Link in Thyroid Cancer
A new study in Cancer Management and Research found a correlation between the age of patients with papillary thyroid cancer and lymph node positivity.
New Breakthrough Therapy Designated for Thyroid Cancer and NSCLC
LOXO-292, which selectively targets RET and has demonstrated preclinical activity against activating RET fusions/mutations, holds promise.
First-of-Kind Trial Studies OS in Post-allograft–Relapsed AML
The research, published in JAMA Oncology, evaluates survival outcomes of a second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion.
FDA Approves First Drug for Advanced cSCC
Cemiplimab (Libtayo), approved for advanced cutaneous squamous cell carcinoma, is intended for those not eligible for curative surgery or radiation.
Will a Novel Combination Become Standard for AML?
A study in The Lancet Haematology suggests this combination could become first-line for elderly or unhealthy patients with newly diagnosed AML.
How Pathology Changed the Lung Care Landscape
In recent years, advances in the molecular analysis of tumors and pathologic investigation have improved understanding of an ambit of lung cancer types.
Three Digital Core Biopsies Sufficient to Determine PD-L1 Expression in NSCLC
Four or more biopsies proffer little additional benefit, found a study presented at the IASLC 19th World Conference on Lung Cancer.
Pembrolizumab Alone or With Chemotherapy for PD-L1–Positive NSCLC?
Pembrolizumab plus chemotherapy failed to improve survival compared with pembrolizumab alone in patients with non–small-cell lung cancer.
Should Dyspnea in Lung Cancer Be Medicated?
Two presentations at the IASLC WCLC 2018 discussed the evidence on treating breathlessness with pharmacologic vs nonpharmacologic therapy.
Eighth Edition of AJCC/TNM Staging System Best at Detecting Survival in Thyroid Cancer
The eighth edition outperforms the seventh edition in predicting survival differences in patients with papillary thyroid cancer and follicular thyroid cancer.
Male Sex Ups Mortality Risk in BRAF V600E Papillary Thyroid Cancer
The study confirmed a significant effect of male sex on PTC-specific patient survival in individuals with the most frequent oncogenic mutation.
FDA Grants Fast-Track Designation to CX-01 for Acute Myeloid Leukemia
CX-01, a low-anticoagulant heparin derivative, has demonstrated good rates of complete remission, rapid platelet recovery, and no serious adverse events.
Targeting the Tumor Microenvironment May Aid in Treatment of Ovarian Cancer
Certain malignancies may possess a common and targetable matrix response, which affects disease pathogeneis, according to a study in Cancer Discovery.
Building a Better Mouse Model for High-Grade Serous Carcinoma
Researchers have developed a mouse model of high-grade serous carcinoma that could prove useful in the preclinical testing of prevention strategies for ovarian cancer.
Novel Early Screening Tool for Ovarian Cancer
Optical coherence tomography and multispectral fluorescence imaging have demonstrated promising results in the early detection of ovarian cancer.
Mogamulizumab Approved for Two Rare Types of Cutaneous T-cell Lymphoma
Mogamulizumab (Poteligeo) is indicated for relapsed or refractory mycosis fungoides or Sézary syndrome following at least one prior systemic therapy.